Empagliflozin and Semaglutide Explored for Endothelial Health in Type 1 Diabetes
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
Background
Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune condition characterized by insufficient insulin production, leading to persistently high blood glucose levels. Patients with T1DM frequently develop endothelial dysfunction, a critical precursor to serious cardiovascular complications like heart attack and stroke, often despite optimized glucose control. This study aimed to investigate whether adding newer antidiabetic drugs, specifically an SGLT2 inhibitor or a GLP-1 receptor agonist, could improve endothelial function and other cardiovascular risk markers in T1DM patients, addressing a significant gap in current T1DM management strategies.